Compare · CELZ vs NU
CELZ vs NU
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Nu Holdings Ltd. (NU): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and NU operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- NU is the larger of the two at $56.33B, about 7023.6x CELZ ($8.0M).
- Over the past year, CELZ is down 17.1% and NU is down 2.6% - NU leads by 14.5 points.
- NU has hit the wire 7 times in the past 4 weeks while CELZ has been quiet.
- NU has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Creative Medical Technology Holdings Inc.
- Nu Holdings Ltd.
- Price
- $2.08-4.59%
- $11.60-3.09%
- Market cap
- $8.0M
- $56.33B
- 1M return
- -6.73%
- -18.54%
- 1Y return
- -17.13%
- -2.60%
- Industry
- Finance: Consumer Services
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 7
- Recent ratings
- 1
- 25
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Nu Holdings Ltd.
Nu Holdings Ltd. operates in the technology industry. The company was incorporated in 2016 and is based in Grand Cayman, Cayman Islands.
Latest CELZ
- SEC Form 10-Q filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
- Amendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.
- SEC Form 10-K filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
Latest NU
- Nu Holdings Announces US$1.0 Billion Share Repurchase Program
- SEC Form 6-K filed by Nu Holdings Ltd.
- Nu Holdings downgraded by Susquehanna with a new price target
- Nu Holdings downgraded by BofA Securities with a new price target
- Nubank Appoints Rob Livingston as Chief Financial Officer
- SEC Form 6-K filed by Nu Holdings Ltd.
- Director Sands Anita M sold $257,042 worth of Class A ordinary shares (21,000 units at $12.24), decreasing direct ownership by 11% to 162,150 units (SEC Form 4)
- SEC Form 144 filed by Nu Holdings Ltd.
- Nu Holdings Ltd. Reports First Quarter 2026 Financial Results
- SEC Form 6-K filed by Nu Holdings Ltd.